Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acne Vulgaris
Research findings from Y. Wang et al update understanding of acne vulgaris
May 4th, 2008
According to a study from the United States, "R-115866 (Rambazole (TM)) is a second-generation retinoic acid metabolism-blocking agent (RAMBA) developed for the treatment of dermatological disorders such as psoriasis and acne vulgaris. Early studies revealed that R-115866 was highly selective for cytochrome P-450 CYP26A1 (IC50 = 4 nM), which is involved in the metabolism of all-trans-retinoic acid (ATRA)." "Orally administered R-115866 proved to be well tolerated in patients with moderate to severe psoriasis or facial acne vulgaris. Clinical studies conducted in patients with moderate to severe psoriasis showed that treatment with R-115866 led to an increase in...
Source: Pharma Investments, Ventures & Law Weekly (2008-05-04)
|
